NeoGenomics is trading 4.46% down at $17.25, with no new company announcement, earnings report, analyst action, or filing found to directly explain the drop.
- The decline extends the August 28 move from $18.05.
- Latest company disclosures were an August 11 general-counsel transition and August 25 securities filings.
- Broader markets are lower, but the S&P 500, Nasdaq Composite, and Dow Jones are each down less than 0.5%, so market weakness alone does not clearly explain NeoGenomics’ larger move.